Data from the phase 3 LIBERTY-CUPID Study C evaluating the investigational use of Dupixent in biologic-naive patients with uncontrolled chronic ...

Pullman & Comley and Day Pitney welcome experienced attorneys to their teams; Lawyers for Good Government announces award ...

SALES FORECAST: The Paris-based group's sales are forecast at 12.63 billion euros, according to Visible Alpha. That compares with 11.96 billion euros for the same period the year before. As of ...

The French drugmaker on Monday announced progress on a deal to sell 50% of its over-the-counter division to Clayton Dubilier ...

Under the proposed deal, the PE firm would take a controlling 50% stake in Sanofi’s Opella unit, with state-owned Bpifrance taking a minority 2% position.

Sanofi will sell a 50% controlling stake in consumer healthcare unit Opella to private equity firm CD&R, with the French ...

Sanofi and private equity firm CD&R are in negotiations to sell a 50% stake in Opella, Sanofi's consumer healthcare division. With a €16B valuation, Opella is the third-largest player in the global ...

Sanofi entered into exclusive talks to sell a controlling stake in its consumer-healthcare business Opella to Clayton ...

Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant ...

This is obviously not the best of times for President Bola Ahmed Tinubu, who since assuming office on May 29, 2023, ...

Clayton Dubilier & Rice is set to buy Sanofi's consumer health unit with social commitments, including job creation ...

This is obviously not the best of times for President Bola Tinubu who since assuming office on May 29, 2023 has turned a globetrotter in search of foreign investors. For records, within his first year ...